<DOC>
	<DOCNO>NCT02417285</DOCNO>
	<brief_summary>CC-122-NHL-001 study multicenter , open-label , phase Ib study dose escalation expansion part . It evaluate safety , tolerability clinical pharmacokinetics CC-122 combination obinutuzumab ( GA101 ) . The study also assess preliminary efficacy combination well pharmacodynamic tumor biomarkers exploratory objective . In dose escalation part , safety tolerability increase dos CC-122 administer fix dose obinutuzumab administer identify maximum tolerate dose . In dose expansion part , patient enrol CC-122 dose select escalation part study combination fix dose obinutuzumab study safety efficacy .</brief_summary>
	<brief_title>A Phase 1b Open-label Study Evaluate Safety Efficacy CC-122 With Obinutuzumab ( GA101 ) Relapsed/Refractory DLBCL iNHL .</brief_title>
	<detailed_description>The one two cohort dose expansion phase ( Part B ) enroll subject relapse refractory follicular lymphoma ( FL ) either refractory relapse treatment lenalidomide-containing regimen ( FL-1 cohort ) never expose lenalidomide ( FL-2 cohort ) . The FL-1 FL-2 cohort enroll 20 and/or 30 subject , respectively .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 2 . ≥ 18 year age old time signing informed consent document . Entry Criteria Specific DoseEscalation Phase ( Part A ) 3 . Subjects CD20 positive , histologically cytologicallyconfirmed , diffuse large Bcell lymphoma ( DLBCL ) ( include transform low grade lymphoma ) relapse refractory disease follow least two prior standard treatment regimen ( eg , RCHOP similar firstlineregimen least one secondline salvage regimen ) and/or autologous stem cell transplant ( ASCT ) chemotherapysensitive patient , follow ASCT EXCEPTIONS : Subjects preASCT set poor prognosis , define primary refractory disease , relapse within 12 month follow firstline treatment ; `` doublehit '' lymphoma Bcl2/Myc gene rearrangement , overexpression high IPI score ( 2,3 ) relapse . Subjects refuse ASCT ASCT appropriate base Investigator 's judgment . Entry Criteria Specific DoseExpansion Phase ( Part B ) 4 . Subjects CD20 positive , histologically confirm ( WHO 2008 classification [ Jaffe , 2009 ] ) , FL ( Grade 1 , 2 , 3a ) relapse refractory disease follow least one prior standard systemic treatment regimen include systemic chemo , immune , chemoimmunotherapy . Systemic therapy include treatment rituximab monotherapy , chemotherapy give without rituximab , radioimmunoconjugates 90Yibritumomab tiuxetan 1311tositumomab . Systemic therapy include , example , H. pylori eradication antibiotic treatment . Lenalidomide naïve 1 . Relapsed refractory follicular lymphoma ( Grade 1 , 2 , 3a ) follow least one prior standard systemic treatment regimen include systemic chemo , immune , chemoimmunotherapy prior exposure lenalidomide ( FL1 cohort ) Lenalidomide expose 2 . Relapsed refractory follicular lymphoma ( Grade 1 , 2 , 3a ) previously treat least two cycle lenalidomidecontaining regimen ( FL2 cohort ) , either single agent combination , experience outcome lenalidomide treatment follow : Early relapse lenalidomide treatment : Subjects relapse within one year last dose lenalidomide ( lenalidomidecontaining regimen ) follow initial response Complete Response ( CR ) lenalidomide ( lenalidomidecontaining regimen ) Early progression lenalidomide treatment : Subjects Progressive Disease ( PD ) within one year last dose lenalidomide ( lenalidomidecontaining regimen ) follow initial response partial response ( PR ) lenalidomide ( lenalidomidecontaining regimen ) Disease refractory lenalidomide : Subjects best response stable disease ( SD ) PD lenalidomide ( lenalidomidecontaining regimen ) without document response PR well treatment lenalidomide ( lenalidomidecontaining regimen ) Lenalidomide lenalidomide contain regimen need immediate prior regimen receive subject eligible entry . Entry Criteria apply Part A Part B 5 . Bidimensionally measurable disease cross sectional imaging compute tomography ( CT ) magnetic resonance imaging ( MRI ) least one lesion &gt; 1.5 cm transverse diameter , define IWG NHL criterion . Measurable disease previously irradiate . 6 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 . 7 . Subjects must follow laboratory value screen : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L without growth factor support 7 day ( 14 day subject receive pegfilgrastim ) . Hemoglobin ( Hgb ) ≥ 8 g/dL . Platelets ( plt ) ≥ 50 x 109/L without transfusion 7 day . Potassium within normal limit correct supplement . AST/SGOT ALT/SGPT ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 5.0 x ULN liver tumor present . Serum bilirubin ≤1.5 x ULN except case Gilberts Syndrome , ≤ 2.0 x ULN Estimated serum creatinine clearance ≥ 60 mL/min use CockcroftGault equation . 8 . Per Pregnancy Prevention Risk Management Plan : 1 . Females childbearing potential ( FCBP ) 1 must undergo pregnancy test base frequency outline Pregnancy Prevention Risk Management Plan ( PPRMP ) pregnancy result must negative . 2 . Unless practice complete abstinence heterosexual intercourse , sexually active female child bear potential ( FCBP ) must agree use adequate contraceptive method specify PPRMP . Complete abstinence acceptable case prefer usual lifestyle subject . Periodic abstinence ( calendar ovulation , symptothermal , postovulation method ) withdrawal acceptable . 3 . Males ( include vasectomy ) must use barrier contraception ( condom ) engage sexual activity FCBP specify PPRMP . 4 . Males must agree donate semen sperm duration specify PPRMP . 5 . All subject must : Understand study drug could potential teratogenic risk . Agree abstain donate blood take study drug follow discontinuation investigational product . Agree share study drug another person . 6 . Other subject , FCBP males able father child handle study drug touch capsule , unless glove wear . 7 . Be counseled pregnancy precaution risk fetal exposure 9 . Able adhere study visit schedule protocol requirement . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . Symptomatic central nervous system involvement . 5 . Any history progressive multifocal leukoencephalopathy ( PML ) . 6 . Known symptomatic acute chronic pancreatitis . 7 . Persistent diarrhea malabsorption ≥ NCI CTCAE Grade 2 , despite medical management . 8 . Peripheral neuropathy ≥ NCI CTCAE ( National Cancer Institute Common Terminology Criteria Adverse Events ) Grade 2 9 . Impaired cardiac function clinically significant cardiac disease , include follow : LVEF ( leave ventricular ejection fraction ) &lt; 45 % determine MUGA ( multigated acquisition scan ) ECHO ( echocardiogram ) . Complete leave bundle branch bifascicular block . Congenital long QT syndrome . Persistent clinically meaningful ventricular arrhythmia . QTcF &gt; 460 msec Screening ECG ( electrocardiogram ) ( mean triplicate recording assess central read ) . Unstable angina pectoris myocardial infarction ≤ 6 month prior start study drug . Troponin T value &gt; 0.4 ng/mL BNP &gt; 300 pg/mL Subjects baseline troponin T &gt; ULN BNP &gt; 100 pg/mL eligible must cardiologist evaluation prior enrollment trial baseline assessment optimization cardioprotective therapy . 10 . Prior ASCT ( autologous stem cell transplant ) ≤ 3 month first dose . 11 . Prior allogeneic stem cell transplant either standard reduce intensity conditioning . 12 . Prior systemic cancerdirected treatment investigational modality ≤ 5 half life 1 month prior start study drug , whichever short , exception : 1 . CD20directed therapy ( eg , rituximab , ofatumumab ) investigational monoclonal antibody within 3 month prior start study drug . 2 . Radioimmunotherapy ( eg , ibritumomab tiuxetan , tositumomab ) within 6 month prior start study drug . 13 . Prior radiotherapy within 1 month prior start study drug . 14 . A major surgery ≤ 2 week prior start study drug . Subjects must recover effect recent surgery therapy might confound safety evaluation study drug . 15 . Prior treatment CC122 obinutuzumab ( GA101 ) . 16 . History severe allergic anaphylactic reaction humanize monoclonal antibody . a. Allergic excipients obinutuzumab . 17 . Known human immunodeficiency virus ( HIV ) infection . 18 . Known chronic active hepatitis B C virus ( HBV , HCV ) infection . 1 . Subjects seropositive due HBV vaccination eligible . 2 . Subjects active viral infection adequate prophylactic HBV reactivation eligible . 19 . Need current chronic systemic corticosteroid therapy ( ≥ 10 mg prednisone per day equivalent dose antiinflammatory corticosteroid ) . . Stable use inhale corticosteroid allow . 20 . Treatmentrelated myelodysplastic syndrome . 21 . Prior history secondary malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 1 year prior start study drug . 22 . Prior immunization live virus vaccine ( within 3 month prior start study drug ) anticipate immunization live virus vaccine duration study . 23 . Pregnant nursing female . 24 . Unwilling unable comply protocol , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Diffused Large B-Cell Lymphoma</keyword>
	<keyword>Phase 1B</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Safety Efficacy</keyword>
	<keyword>CC-122</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>GA101</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>